ClinicalTrials.gg
RecruitingNCT05176704Updated Oct 14, 2026

Development of Eye-movement Based Biomarkers in Alzheimer's Disease

An observational study in Alzheimer's Disease and Healthy Controls, sponsored by McGill University. Recruiting at 5 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by McGill University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 14, 2026Start date movedPrimary completion moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 321 studies in Alzheimer Disease with a site in Canada — 60 open to participants now, 81 under way, 23 of them phase 3. Alzheimer Disease · Canada.

Planned enrollment
27th of 39
250 · median 500
Started
2026
with 14 others
Observational
39 of 321
16 open now
Primary completion
2027-11
later than 38 of 80 live
Registered
235th of 321
by date

Among the 321 studies in Alzheimer Disease with a site in Canada, this one is the 27th largest by planned enrollment of the 39 observational ones that give a count, is one of 15 that started in 2026, is one of 39 observational ones, reaches primary completion later than 38 of the 80 other live ones, and was the 235th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

60 of the 321 studies in Alzheimer Disease with a site in Canada are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Alzheimer Disease with a site in Canada, or all of them as a file.
02

Study summary

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.

This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by Alzheimer's Disease and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of Alzheimer's Disease and associated cognitive changes.

03

Conditions studied

  • Alzheimer's Disease
  • Healthy Controls

Browse trials for

Keywords

  • Alzheimer's Disease
  • Eye Movement Biomarkers
  • eye-tracking
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

For this study, we will recruit 250 participants. 125 will be AD patients (including predominant AD with mixed vascular and MCI due to AD), and 125 will be age-matched healthy cognitively intact control participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all participants:

    1. Able to provide
    2. Aged 18 years or older at the time of enrollment
    3. Able to read in either French or English
    4. Able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses.
  • For patients only:

    1. Confirmed diagnosis of AD based on the NIAAA diagnostic criteria of probable AD

Exclusion criteria

Exclusion Criteria:

  • For AD participants:

    1. Diagnosed with one of the following dementia subtypes: Fronto-temporal dementia, Lewy-body dementia, or Creutzfeldt-Jakob disease.
    2. Incapacity to provide or inability to adequately understand the task instructions.
  • For all participants:

    1. Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control.
    2. Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia).
    3. Diagnosis of macular edema or other pre-existing ocular conditions (e.g., glaucoma, cataracts) that would prevent from performing the eye movement assessments.
    4. Unstable medication use: recent (less than one month from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to have an effect on ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. Occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period of an eye movement assessment.
    5. Diagnosed with an active substance use disorder.
    6. History of stroke may be considered an exclusion criterion, at the discretion of the PI, if judged to potentially affect the cerebral network underlying eye movements and gaze control.
    7. Recent traumatic brain injury (within the last 6 months).
  • For healthy controls only:

    1. Evidence or history of significant neurodegenerative disorder affecting brain function (e.g., MS, PD, ALS, Non-AD Dementia).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Alzheimer's Patients

    125 participants will be AD patients (including predominant AD with mixed vascular and MCI due to AD)

    Device: Eye-Tracking

  • Healthy Control

    125 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.

    Device: Eye-Tracking

Interventions

  • DeviceEye-Tracking

    Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

06

What researchers measure

Primary outcomes

  1. Clinical Dementia Rating (CDR) score, one time, at the day of enrollment.

    The Clinical Dementia Rating (CDR) is a global rating scale for staging patients diagnosed with Alzheimer disease and other dementias and monitoring changes in the level of there disabilities over time. The CDR scale is a 0-3 point numeric scale (0.5 unit increments) derived from clinician rating of cognition and daily function in the domains of memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.

    Time frame: Baseline

Secondary outcomes

  1. The Montreal Cognitive Assessment (MoCA) score, one time, at the day of enrollment.

    The Montreal Cognitive Assessment (MoCA) is a brief 30-question cognitive screening test designed to assist Health Professionals in the detection of mild cognitive impairment and Alzheimer's disease. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal.

    Time frame: Baseline

  2. The Mini-Mental State Exam (MMSE) score, one time, at the day of enrollment.

    The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly, it includes tests of orientation, attention, memory, language and visual-spatial skills. It consists of a series of questions and tests that can be used by clinicians to help diagnose dementia and to help assess its progression and severity.

    Time frame: Baseline

07

Study locations

4 of 5 sites recruiting
  • Elogia, a Residence of Groupe Maurice
    Montreal, Quebec H1V 1A1, Canada
    Recruiting
  • ORA, A residence of Groupe Maurice
    Montreal, Quebec H2M 0A9, Canada
    Not yet recruiting
  • Cornelius, a Residence of Groupe Maurice
    Montreal, Quebec H2Y 2H1, Canada
    Recruiting
  • The Douglas Research Centre
    Montreal, Quebec H4H 1R3, Canada
    Recruiting
  • The Montreal Neurological Institute
    Ville-Marie, Quebec H3A 2B4, Canada
    Recruiting
    • Lydia Ouellet · Contactlydia.ouellet@mcgill.ca · 514-398-1445
    • Simon Ducharme, MD MSc FRCP · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Apr 2022 → May 2026, primary completion Mar 2024 → Nov 2027 and completion Mar 2024 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Jan 4, 2022
StartActual
May 19, 2026was Apr 2022
Primary completionEst.
Nov 30, 2027was Mar 2024
CompletionEst.
Nov 30, 2027was Mar 2024
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed
Show 5 added (5 Canada)
  • Elogia, a Residence of Groupe Maurice · Montreal, Canada
  • ORA, A residence of Groupe Maurice · Montreal, Canada
  • Cornelius, a Residence of Groupe Maurice · Montreal, Canada
  • The Douglas Research Centre · Montreal, Canada
  • The Montreal Neurological Institute · Ville-Marie, Canada
Show 1 removed
  • The Douglas Research Centre · Montréal, Canada
Oct 14, 2026
Start date
Apr 15, 2022→May 19, 2026
Oct 14, 2026
Primary completion
Mar 3, 2024→Nov 30, 2027
Oct 14, 2026
Study completion
Mar 3, 2024→Nov 30, 2027
Oct 14, 2026
Eligibility
1 inclusion criterion added, 3 removed; 1 exclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedVisual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc. are permitted)
  • AddedAble to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses.
  • RemovedHaving undergone a full neuropsychological evaluation within the last 6 months or having a planned full neuropsychological evaluation within the next 6 months.
  • RemovedAD diagnoses supported by FDG-PET scan or amyloid biomarkers (CSF or amyloid PET)
Exclusion criteria
  • RemovedHistory of stroke.
  • AddedHistory of stroke may be considered an exclusion criterion, at the discretion of the PI, if judged to potentially affect the cerebral network underlying eye movements and gaze control.
Oct 14, 2026
Interventions
Arms added: Alzheimer's Patients; arms removed: CDR = 0.5·CDR = 1·CDR = 2·CDR = 3
Oct 14, 2026
Contact
Study contact changed: n•••@ssss.gouv.qc.ca · •••6131→l•••@mcgill.ca · •••9016. See the current contact
Oct 14, 2026
Title
Development and Validation of a Novel Functional Eye-Tracking Software Application formovement Based Biomarkers in Alzheimer's Disease
Oct 14, 2026
Sponsor
Innodem Neurosciences→McGill University
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    5 sites added, 1 site removed
    Show 5 added (5 Canada)
    • Elogia, a Residence of Groupe Maurice · Montreal, Canada
    • ORA, A residence of Groupe Maurice · Montreal, Canada
    • Cornelius, a Residence of Groupe Maurice · Montreal, Canada
    • The Douglas Research Centre · Montreal, Canada
    • The Montreal Neurological Institute · Ville-Marie, Canada
    Show 1 removed
    • The Douglas Research Centre · Montréal, Canada
    Start date Apr 15, 2022→May 19, 2026
    Primary completion Mar 3, 2024→Nov 30, 2027
    Study completion Mar 3, 2024→Nov 30, 2027
    Eligibility 1 inclusion criterion added, 3 removed; 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedVisual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc. are permitted)
    • AddedAble to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses.
    • RemovedHaving undergone a full neuropsychological evaluation within the last 6 months or having a planned full neuropsychological evaluation within the next 6 months.
    • RemovedAD diagnoses supported by FDG-PET scan or amyloid biomarkers (CSF or amyloid PET)
    Exclusion criteria
    • RemovedHistory of stroke.
    • AddedHistory of stroke may be considered an exclusion criterion, at the discretion of the PI, if judged to potentially affect the cerebral network underlying eye movements and gaze control.
    Interventions Arms added: Alzheimer's Patients; arms removed: CDR = 0.5·CDR = 1·CDR = 2·CDR = 3
    Sponsor Innodem Neurosciences→McGill University
    Contact Study contact changed: n•••@ssss.gouv.qc.ca · •••6131→l•••@mcgill.ca · •••9016. See the current contact
    Title Development and Validation of a Novel Functional Eye-Tracking Software Application formovement Based Biomarkers in Alzheimer's Disease
    + 3 other changes: verification date, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05176704
Lead sponsor
McGill University
Responsible party
Simon Ducharme (Principle Investigator, McGill University) — Principal investigator
First posted
Jan 4, 2022
Start date
May 19, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Luciano Buonamici
Contact
luciano.buonamici@mcgill.ca
514-399-9016

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion